Hypercalcemia in patients with oral squamous cell carcinoma
| Autor: | Youichi Kurachi, M. Nakamura-Mitsuhashi, Masao Nagumo, Masayasu Iwase, Saburou Kakuta, Hideaki Sakamaki |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Calcitonin Male medicine.medical_specialty Serum albumin Pamidronate Malignancy Gastroenterology Internal medicine medicine Carcinoma Biomarkers Tumor Humans Stage (cooking) General Dentistry Aged Neoplasm Staging Aged 80 and over Parathyroid hormone-related protein biology Diphosphonates business.industry Parathyroid Hormone-Related Protein Cancer Proteins Retrospective cohort study Radioimmunoassay Middle Aged medicine.disease Prognosis Neoplasm Proteins Endocrinology biology.protein Carcinoma Squamous Cell Hypercalcemia Female Mouth Neoplasms business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Clinical oral investigations. 5(3) |
| ISSN: | 1432-6981 |
| Popis: | Humoral hypercalcemia of malignancy (HHM) is one of the most common metabolic complications associated with cancer. A retrospective study of hypercalcemia in patients with squamous cell carcinoma of the oral cavity was undertaken. All patients were periodically monitored for their serum level of calcium (Ca). Hypercalcemia was defined as a serum Ca concentration higher than 11 mg/dl of the correction for serum albumin concentration. The serum levels of parathyroid hormone related protein (PTH-rP) were also measured by radioimmunoassay. Hypercalcemia was detected in ten of 246 patients (4.1%). All ten patients were at an advanced stage of oral squamous cell carcinoma (SCC, Stage IVA, IVB or IVC). In these ten patients, the serum level of PTH-rP was significantly elevated, 238 +/- 91 pmol/l (range, 108-380 pmol/L). The patients with HHM who underwent antihypercalcemic therapy showed reduced Ca levels relating to PTH-rP levels; however, the Ca concentration was temporarily improved after anti-hypercalcemic treatment. The median survival time after diagnosis of HHM was only 55.8 +/- 19.9 days (range, 27-86 days). HHM in oral cancer is likely attributable to PTH-rP, and its occurrence appears to be an ominous prognostic sign. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink